68 results about "Thymoquinone" patented technology

The invention describes a nutraceutical composition and method for preventing / treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.

Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w / w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

The present invention reported that SFE is suitable for Nigella sativa seeds oil extraction and fractionation. TQRF that were produced through SFE extractions (600 bars / 40° C.) and fractionations (100-200 bars / 40-60° C.) possessed high level of TQ and antioxidant activity. SFE fractionation efficiently concentrates the TQ content and antioxidant activity of Nigella sativa seeds oil in short time and low cost manners without using any hazardous organic solvents.

Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w / w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

The present invention reported that SFE is suitable for Nigella sativa seeds oil extraction and fractionation. TQRF that were produced through SFE extractions (600 bars / 40° C.) and fractionations (100-200 bars / 40-60° C.) possessed high level of TQ and antioxidant activity. SFE fractionation efficiently concentrates the TQ content and antioxidant activity of Nigella sativa seeds oil in short time and low cost manners without using any hazardous organic solvents.

A method for cultivating Monarda fistulosa for production of thymoquinone includes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. The heavy rate of planting produces plants bearing oil without weed contamination and reduces herbicide use due to production of natural herbicides by the monarda plants. Seeding and mowing the first season, and harvesting in seasons thereafter reduce costs. The method results in increased production of essential oils including thymoquinone and thymohydroquinone at levels up to about 40% or more of recovered oils, and which may be distilled from the plant.

A method of controlling target aquatic microorganism pest populations by exposing the target population to an effective amount of an aquacidal compound. The aquacidal compounds are selected from the group consisting of quinones, anthraquinones, naphthalenediones, quinine, warfarin, coumarins, amphotalide, cyclohexadiene-1,4-dione, phenidione, pirdone, sodium rhodizonate, apirulosin and thymoquinone. The method is particularly effective for treating ballast water of ships or other enclosed volumes of water subject to transport between or among geographic areas to control the relocation of plants, toxic bacteria, and animals contained in the water.

Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w / w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

This invention relates to stable capsule formulations for pharmaceutical, nutraceuticals or food supplements which contain thymoquinone (THQ) as an active ingredient, and which can be stored at room temperature without significant loss of THQ during the shelf life of the capsules. The preferred capsules have a hydroxypropylmethylcellulose (HPMC) shell and may contain carvacrol as an additional active ingredient, either in synthetic form, or as part of a plant extract. Optionally, the capsules may contain a viscosity agent.

Low-temperature syntheses of thymoquinone / harmaline compounds are provided which give increased yields of desirable products having molecular weights of from about 360-380. The syntheses involve carrying out reactions between thymoquinone and harmaline and a non-interfering solvent at a temperature of less than about 10° C.

The nano-liposomal aminoglycoside-thymoquinone formulations are suitable for administration to a mammal and include an aminoglycoside antibiotic (amikacin, gentamicin, or tobramycin) and thymoquinone (TQ) encapsulated within a liposome. The liposome-encapsulated aminoglycoside-thymoquinone (TQ) formulations can be administered to a subject in need thereof. The liposome-encapsulated aminoglycoside-thymoquinone formulations are prepared by a method, which comprises forming a lipid film from a mixture of phospholipids and cholesterol; mixing the lipid film with methanol containing thymoquinone in molar ratio; evaporating off the methanol from the mixture; adding polysaccharides and / or polyethylene glycol (PEG) in PBS (phosphate-buffered saline) buffer in volume ratio to form a liposomal mixture; sonicating the liposomal mixture for at least five minutes; adding an aminoglycoside antibiotic in molar ratio with the thymoquinone; sonicating the mixture for at least five minutes; lyophilizing the liposomal aminoglycoside-thymoquinone formulation; and storing it at −80° C. until use.

The present invention refers to thymoquinone, a main constituent of the volatile oil of Nigella sativa, and its protective effect against sepsis syndrome morbidity, mortality and associated organ dysfunctions. In particular, the present invention refers to thymoquinone for use in the prevention and / or treatment of sepsis syndrome. The present invention further refers to a pharmaceutical composition and a kit.

New compositions of matter useful for the treatment of human diabetes and cancers comprise the reaction products of thymoquinone and harmaline or harmaline-like compounds, such as β-carboline compounds, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and / or α-hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation α-hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

A method for cultivating Monarda fistulosa for production of thymoquinone includes planting seeds at rates between about 2.5 and about 5 pounds per acre, preferably about 4 pounds per acre. The heavy rate of planting produces plants bearing oil without weed contamination and reduces herbicide use due to production of natural herbicides by the monarda plants. Seeding and mowing the first season, and harvesting in seasons thereafter reduce costs. The method results in increased production of essential oils including thymoquinone and thymohydroquinone at levels up to about 5% of recovered oils, and which may be distilled from the plant.

The invention provides a hyaluronic acid-adipodihydrazide-thymoquinone grafted polymer as well as a synthesis method and application of the hyaluronic acid-adipodihydrazide-thymoquinone grafted polymer, belonging to the field of pharmaceutical preparations. The synthesis method comprises the steps of firstly, synthesizing hyaluronic acid-adipodihydrazide; then, grafting thymoquinone; finally, forming the hyaluronic acid-adipodihydrazide-thymoquinone grafted polymer. Compared with the prior art, the synthesis method has the advantages that adipodihydrazide is used as a link span, and thymoquinone is connected to hyaluronic acid, so that the obtained grafted polymer has the characteristic of pH sensitivity release, and the targeting property of thymoquinone to tumors can be remarkably improved.

The invention discloses a method for extracting thymoquinone in nigella plant seeds on the basis of a microwave-assisted solvent extraction method and separating the thymoquinone in nigella plant seeds by virtue of silica gel column chromatography. The method comprises the following steps: extracting: weighing the crushed nigella plant seeds, adding absolute ethyl alcohol according to a certain ratio of material to liquor, extracting under the condition of the microwave irradiation power of 400-700W, filtering, thereby obtaining solid filter residues and thymoquinone extracting solution; repeatedly extracting the filter residues for 1-2 times according to the previous extraction step, and mixing the extracting solution; and separating and purifying: recycling the solvent from the extracting solution at a low temperature until the solution is dry, adding a proper amount of petroleum ether-ethyl acetate (9:1) solution for dissolving, totally transferring the dissolving solution to the top end of the pretreated silica gel chromatography column, eluting by using petroleum ether-ethyl acetate (8:2), collecting the eluent, performing vacuum concentration on the eluent, drying at a low temperature, thereby obtaining the thymoquinone.

A method of producing thymoquinone and / or thymohydroquinone in Monarda by growing Monarda with elevated levels of carvacrol and / or thymol in the fresh plant tissue and vigorous growth, harvesting the Monarda, leaving the Monarda to senensce in the presence of oxygen and extracting the thymoquinone and / or thymohydroquinone from the senesced tissue.

Described are compositions containing quinones that show activity in enhance DNA repair and / or prevent damage to DNA and / or upregulate genes associated with wound healing. The quinones are thymoquinone, lapachol, myrtucommulone C, or mixtures thereof, and can be formulated into cosmetic compositions for topical administration to a subject in need thereof. The cosmetic compositions can also include sunscreens, surfactants, sunless tanning agents, desquamation agents, antiperspirants, colorants, preservatives and mixtures; and a cosmetically acceptable carrier. The compositions should find use in methods for treating the signs of ageing in mammals, dermatitis and wound healing via topical application to a site in need thereof, such as the skin or hair of the mammals or a wound site.

New compositions of matter useful for the treatment of human diabetes and cancers comprise the reaction products of thymoquinone and harmaline or harmaline-like compounds, such as β-carboline compounds, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

A method of controlling target aquatic microorganism pest populations by exposing the target population to an effective amount of an aquacidal compound. The aquacidal compounds are selected from the group consisting of quinones, anthraquinones, naphthalenediones, quinine, warfarin, coumarins, amphotalide, cyclohexadiene-1,4-dione, phenidione, pirdone, sodium rhodizonate, apirulosin and thymoquinone. The method is particularly effective for treating ballast water of ships or other enclosed volumes of water subject to transport between or among geographic areas to control the relocation of plants, toxic bacteria, and animals contained in the water.

A method of controlling target aquatic microorganism pest populations by exposing the target population to an effective amount of an aquacidal compound. The aquacidal compounds are selected from the group consisting of quinones, anthraquinones, naphthalenediones, quinine, warfarin, coumarins, amphotalide, cyclohexadiene-1,4-dione, phenidione, pirdone, sodium rhodizonate, apirulosin and thymoquinone. The method is particularly effective for treating ballast water of ships or other enclosed volumes of water subject to transport between or among geographic areas to control the relocation of plants, toxic bacteria, and animals contained in the water.

New compositions of matter useful for the treatment of human diabetes and cancers comprise the reaction products of thymoquinone and harmaline or harmaline-like compounds, such as β-carboline compounds, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

New compositions of matter useful for the treatment of human diabetes and cancers comprise the reaction products of thymoquinone and harmaline or harmaline-like compounds, such as β-carboline compounds, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

A method of preventing and / or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder.